Immutep Limited (IMMP)

CIK 0001506184 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest FY-2025 —
FY-2024 —
FY-2023 —

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover Page
—
Statements
Consolidated Balance Sheets
—
Consolidated Statements of Comprehensive Income
—
Consolidated Statements of Cash Flows
—
Consolidated Statements of Changes In Equity
—
Notes
Cash and Cash Equivalents
—
Commitments For Expenditure
—
Contingent Liabilities
—
Contributed Equity
—
Critical Accounting Judgements, Estimates and Assumptions
—
Current Liabilities
—
Current Receivables
—
Cybersecurity Risk Management and Strategy Disclosure
—
Deferred Tax Balances
—
Derivative Financial Asset
—
Dividends
—
Earnings Per Share
—
Equity
—
Events Occurring After The Reporting Date
—
Expenses
—
Financial Risk Management
—
Income Tax Expense
—
Insider Trading Policies and Procedures
—
Key Management Personnel Disclosures
—
Leases
—
Non Current Liabilites
—
Non Current Liabilities
—
Non-current Assets
—
Non-current Liabilities
—
Other Current Assets
—
Other Non-current Assets
—
Parent Entity Information
—
Reconciliation of Loss After Income Tax To Net Cash Used In Operating Activities
—
Related Party Transactions
—
Remuneration of Auditors
—
Segment Reporting
—
Share-based Payments
—
Short Term Investments
—
Subsidiaries
—
Summary of Significant Accounting Policies
—